文献速递药疹与重症皮肤不良反应

重症皮肤不良反应中药物诱导干扰素γ释放细胞与淋巴细胞增殖的检测

The measurement of drug-induced interferon γ-releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-03-13

本研究纳入23例重症皮肤不良反应患者,在急性期检测药物特异性干扰素γ释放细胞、恢复期行淋巴细胞转化试验。急性期73.9%可检出药物特异性干扰素γ释放细胞,恢复期淋巴细胞转化试验阳性率52.2%,两者显著相关(r=0.65,P<0.01)。作者认为急性期需紧急识别致敏药物时,干扰素γ酶联免疫斑点法可能是有用工具。

要点

  • 急性期药物特异性干扰素γ释放细胞检出率为73.9%(23例重症皮肤不良反应患者)。
  • 恢复期淋巴细胞转化试验阳性率为52.2%。
  • 干扰素γ酶联免疫斑点法与淋巴细胞转化试验结果显著相关(r=0.65,P<0.01)。

核心结论

  • 在急性期需紧急识别致敏药物时,干扰素γ酶联免疫斑点法可能是识别重症皮肤不良反应患者致敏药物的有用工具。

研究设计与样本

  • 采集23例重症皮肤不良反应患者急性期和恢复期的外周血单个核细胞,分别检测药物特异性干扰素γ释放细胞和淋巴细胞增殖。

主要发现

  • 73.9%的重症皮肤不良反应受试者可检出药物特异性干扰素γ释放细胞,其中使用全身性类固醇激素者为55.6%、未使用者为85.7%。
  • 淋巴细胞转化试验在52.2%的重症皮肤不良反应受试者中为阳性。
  • 淋巴细胞转化试验阳性者的药物特异性干扰素γ释放细胞频率显著高于阴性者(260.1 ± 110.0 对 46.6 ± 20.7 细胞/10⁶ 外周血单个核细胞,P = 0.01)。
  • 干扰素γ酶联免疫斑点法与淋巴细胞转化试验结果呈显著相关(r = 0.65,P值 <0.01)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The lymphocyte transformation test (LTT) is a standard laboratory method to identify culprit drugs in patients with a history of drug-induced non-immediate hypersensitivity and is mainly performed during the recovery phase. The measurement of drug-specific interferon γ (IFN-γ)-releasing cells has been introduced to confirm culprit drugs, even during the acute phase of drug allergy. OBJECTIVES: This study aimed to evaluate the capability of the enzyme-linked immunospot assay (ELISpot) to detect drug-specific IFN-γ-releasing cells during the acute phase and the capability of LTT to identify culprit drugs during the recovery phase in patients presenting with severe cutaneous adverse reactions (SCARs). METHODS: Peripheral blood mononuclear cells (PBMCs) from 23 SCAR patients were collected during the acute and recovery phases and assayed for drug-specific IFN-γ-releasing cells and lymphocyte proliferation, respectively. RESULTS: Drug-specific IFN-γ-releasing cells were detectable in 73.9% of SCAR subjects (55.6% and 85.7% in patients who were and were not taking systemic steroids, respectively), whereas LTT results were positive in 52.2% of SCAR subjects. The frequencies of drug-specific IFN-γ-releasing cells were significantly higher in patients with positive LTT than in those with negative LTT (260.1 ± 110.0 and 46.6 ± 20.7 cells/106 PBMCs, P = 0.01). A significant correlation between the results of the IFN-γ ELISpot assay and LTT was demonstrated (r = 0.65, P value <0.01). CONCLUSION: The IFN-γ ELISpot assay could be a useful tool to identify culprit drugs in SCAR patients when culprit drug identification is urgently needed during the acute phase of drug allergy.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Suthumchai N, Srinoulprasert Y, Thantiworasit P, et al. The measurement of drug-induced interferon γ-releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions. J Eur Acad Dermatol Venereol. 2018. PMID: 29478292. doi:10.1111/jdv.14890

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。